Morepen Laboratories Ltd
NSE: MOREPENLAB BSE: 500288
₹41.29
(-1.46%)
Mon, 27 Apr 2026, 11:33 pm
Market Cap22.97B
PE Ratio22.75
Dividend0.48
Health Technology
Pharmaceuticals: Major
24.5KMorepen Laboratories Analysis
dividend
- Unable to evaluate Morepen Laboratories's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Morepen Laboratories's dividend against the top 25% market benchmark as the company has not reported any payouts.
health
- Morepen Laboratories is profitable, therefore cash runway is not a concern.
- Morepen Laboratories is profitable, therefore cash runway is not a concern.
- Debt is covered by short term assets, assets are 2.2x debt.
- Morepen Laboratories's cash and other short term assets cover its long term commitments.
- Interest payments on debt are well covered by earnings (EBIT is 27.2x coverage).
- Morepen Laboratories's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
- Operating cash flow is negative therefore debt is not well covered.
- The level of debt compared to net worth has increased over the past 5 years (28.7% vs 64.2% today).
- Morepen Laboratories's level of debt (64.2%) compared to net worth is high (greater than 40%).
- High level of physical assets or inventory.
management
- The average tenure for the Morepen Laboratories board of directors is over 10 years, this suggests they are a seasoned and experienced board.
- Sushil's remuneration is lower than average for companies of similar size in India.
- Sushil's compensation has been consistent with company performance over the past year, both up more than 20%.
- The average tenure for the Morepen Laboratories management team is over 5 years, this suggests they are a seasoned and experienced team.
misc
- Morepen Laboratories is not covered by any analysts.
- Morepen Laboratories has significant price volatility in the past 3 months.
past
- Morepen Laboratories's 1-year earnings growth exceeds its 5-year average (31.3% vs 23.6%)
- Morepen Laboratories has delivered over 20% year on year earnings growth in the past 5 years.
- Morepen Laboratories has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
- Morepen Laboratories's earnings growth has exceeded the IN Pharmaceuticals industry average in the past year (31.3% vs 22.7%).
- Morepen Laboratories used its assets less efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
- Morepen Laboratories has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
value
- MOREPENLAB outperformed the Pharmaceuticals industry which returned 26.7% over the past year.
- MOREPENLAB outperformed the Market in India which returned -14.5% over the past year.
- NSEI:MOREPENLAB is up 58.3% outperforming the Pharmaceuticals industry which returned 6.8% over the past month.
- NSEI:MOREPENLAB is up 58.3% outperforming the market in India which returned 8% over the past month.
- Morepen Laboratories is overvalued based on assets compared to the IN Pharmaceuticals industry average.
- Morepen Laboratories is overvalued based on earnings compared to the IN Pharmaceuticals industry average.
- Morepen Laboratories is overvalued based on earnings compared to the India market.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800